Effect of octreotide on cells p rolifera tion and apop tosis in hum an gastric cancer cell line

Transcription

1 1426 BGC , 2, 1, 1, 1, 1 Effect of octreotide on cells p rolifera tion and apop tosis in hum an gastric cancer cell line BGC SUN Hai - ying, ZHANG L i, L I Guo - qing, L IU Hong - ying, CHEN Fang - zhi The Second A ffiliated Hospital of U niversity of South China, Hengyang , China. AbstractO bjective: To study the effect of octreotide (OCT) on p roliferation, apop tosis and cell cycle in human gastric cancer cell line BGC in vitro, and further to exp lore the possible mechanism of inhibition. M ethods: Human gastric cancer cell line BGC was treated with Octreotide. 5 - FU was used as positive control. MTT assay and AO - EB fluorescent staining as well as flow cytometry were performed in this study. Results: Octreotide inhibi2 ted the growth and p roliferation of BGC in vitro within certain concentrations. The supp ression was dose - de2 pendent, time - dependent, and had staturability. Morphological variations of apop tosis were observed after treated with OCT, the apop totic rate measured by AO - EB fluorescent staining and flow cytometry had statistical significance com2 pared with negative group ( P < 005). G 1 phase rate gradually increased, S phase rate gradually decreased, cell cycle was arrested at G 1 phase in human gastric cancer cell line BGC treated by OCT. Conclusion: Octreotide can inhibit the p roliferation of human gastric cancer cell line BGC in vitro. It m ight be related with inducing apop to2 sis and arresting cell cycle at G 1 /S phase. Key words gastric cancer; octreotide; BGC - 823; p roliferation; apop tosis Modern Oncology 2009, 17 (08) : : (octreotide, OCT)BGC :OCTBGC - 823,5 - FU, MTT,, AO - EB : OCTBGC - 823, ; OCT, AO - EB ( P < 0. 05) ; BGC - 823OCT, G 1, S, G 1 /S : g/l OCT BGC - 823, G 1 /S ;; BGC - 823; ; R A (2009) (octreotide, OCT),, OCTBGC - 823, [ 1 ] : ( Y ) 1, , ( ),,,, ( ),,,,,, [ 2-4 ],, OCT( ), 5 - FU ( ), (MTT) (DM2 SO) ( Sigma ),( FBS) ( ), RPM I1640 ( GIBCO BRL ), AO - EB(), 96 6 (Nunc),(, CliniB io 128), (Becton D ickinson ) 1. 2 BGC %RP2

2 M I1640,37 5% CO %, ( 5 - FU 100mg/L ) OCT( g/l) 1. 4(M TT) BGC - 823, 0. 25%,RPM I / m l,96, 100l/, 100l 37 5% CO 2 24hRP2 M I164024, :. () ;. ( 5 - FU,100mg/L ) ; -. OCT, g/l MTT(5mg/m l) 20l, 4,, DMSO150l, 10m in,30m in 570nm (A490) ( inhibitory rate, IR) := (OD- OD) /OD 100% 1. 5 ( AO - EB ) BGC /m l,6 (Nunc), 2 m l, 6 h, MTT,OCT g/l, 48h, PBS 0. 5m l AO - EB, 5 PBS,,, DHFO lympus, OCTBGC ( g/l ) 10-3 g/l ( ), 4PBS 2, 500 rpm 8m in,, 75 %, EP, 4 : RnaseAPBS 200l, 3745m in; 500 rpm 8m in, 4PBS 200l; ( P I), 50g/m l,,45m in - 60m in; 300,, 10000, 1. 7 ( gx s), SPSS13. 0, P < OCTBGC , BGC ,OCT 2 BGC - 823,, g/l,,, g/l 1 OCT BGC OCT BGC g/loctbgc - 823, g/l OCT ( P < 0. 05), ; 10-2 g/l 10-3 g/l, BGC , 48, 48 BGC - 823,48 (1) 10-3 g/loct BGC FU ( P < 0. 05) 1OCTBGC OD( gx s) 24h 48h 72h ( % ) 24h 48h 72h 5 - FU ( ) a a a OCT( g/l) a a a a a a ab ab ab ac abc abc : a ( P < 0. 01) ; b5 - FU ( P > 0. 05) ; c 10-3 ( P > 0. 05) 2. 3AO - EB OCT,,,,,,,,

3 1428 O lympus 200,,OCT ( P < 0. 01) ( 2,2) 2OCT 48AO - EB OCT ( g/l) ( gx s) ( % ) a a a : a P < BGC g/l 48 h,,,, ( P < 0. 05) (3) 10-3 g/loct ,,( P < 0. 05) (4) OCT 48h, G 1 /S, G 1, S,, ( 3,3) 3OCT BGC G 1 S ( gx s) OCT ( % ) G 1 ( % ) S( % ) a a a a a a a a a : a P < g/loct BGC ( % ) 0h 12h 24h 48h : a0hp < ( % ) ( gx s) a a a 3 2 OCT 48AO - EB A: 0g/L ( 200) ; B: 10-5 g/l ( 200) ; C: 10-4 g/l ( 200) ; D: 10-3 g/l ( 200) SS : SSSSTR, [ 5 ] (),(), : SS SSTR,( [ 8 ] ( EGF) - 1 ( IGF - 1) [ 6 ] SS MTT: g/ LOCTBGC - 823, ( P < 0. 05), OCT g/l BGC - 823, OCT10-2 g/l BGC - 823, OCT [ 7 ], 48 BGC - 823,48, [ 9 ]

4 , 3 OCTBGC A: 0g/L ( 200) ; B: 10-5 g/l ( 200) ; C: 10-4 g/l ( 200) ; D: 10-3 g/l ( 200) Pages [ 10 ] RC P27Kip l,g 1 S : OCT BGC , G 1 /S, pages BGC SSTR2mRNA,OCT SSTR5 SSTR2 [ 11 ], OCT SSTR2 BGC G 1 /S,,, : OCT BGC - 823,, G 1 /S,,, p53, bax, Ferrante [ 12 ] p53 p63 p73bcl - 2 Bax B ID B IK TNFSF8SSTR2,,,, [ 1 ] Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents[ J ]. Ann Oncol, 2006, 17 (12) : [ 2 ] Guillermet - Guibert J, Lahlou H, Cordelier P, et al. Physiology of somatostatin recep tors[ J ]. J Endocrinol Invest, 2005, 28 ( 11 Sup2 p l) : 5-9. [ 3 ] Tejeda M, Gaal D, Hullan L, et al. Evaluation of the antitumor effi2 cacy of the somatostatin structural derivative TT on different tumor models[ J ]. Anticancer Res, 2006, 26 (5A) : [ 4 ] Erlandsen SE, Fykse V,W aldum HL, et al. Octreotide induces ap2 op tosis in the oxyntic mucosa [ J ]. Mol Cell Endocrinol, 2007, 264 (1-2) : [ 5 ] Patel YC. Somatostatin and its recep tor fam ily [ J ]. Front Neuroen2 docrinol, 1999, 20 (3) : [ 6 ] Berruti A, Dogliotti L, Mosca A, et al. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin - A, p rostate - specific antigen, and insulin - like growth factor - 1 in advancedprostate cancer patients [ J ]. Prostate, 2001, 47 ( 3 ) : [ 7 ] Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide p romotes ap2 optosis in human somatotroph tumor cells by activating somatostatin recep tor type 2 [ J ]. Endocr Relat Cancer, 2006, 13 ( 3 ) : [ 8 ],,. MKN45 [ J ]., 2002, 10 (1) : [ 9 ],. [ J ]., 2002, 22 (4) : [ 10 ] Pages P, Benali N, Saint - Laurent N, et al. sst2 somatostatin re2 cep tor mediates cell cycle arrest and induction of p27 ( Kip1). Ev2 idence for the role of SHP - 1 [ J ]. J B iol Chem, 1999, 274 ( 21) :

5 1430 [ 11 ],. 2 mrna [ J ]., 2000, 22 (5) : [ 12 ] Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide p romotes ap2 op tosis in human somatotroph tumor cells by activating somatosta2 tin recep tor type 2 [ J ]. Endocr Relat Cancer, 2006, 13 (3) : ( : ) TCT,, TCT qua lity control and the diagnosis of cervica l ca rcinom a W EN Shou - qing, Q IU L i, ZHONG Mei - lian D epartm ent of Pathology, B ao an People s Hospital of Shenzhen city, Shenzhen , China. AbstractO bjective: To discuss quality control method of Thinp rep cytologic test( TCT). M ethods: The p rocess of quality control method including drawing materials, smear, dye was analyzed in cases. The positive diagnosis was screened including cervical carcinoma, high grade squamous intraep ithelial lesion. The results were compared with HPV DNA detection and biop sies. Results: 98. 8% (18287 /18500) samp les were screened excellently by TCT. TCT were able to detect 100% (18 /18) of squamous cell carcinoma, 97% (30 /31) C IN III frade and 90% ( 42 /46) C IN IIgrade. Conclusion: TCT slides quality control could imp rove the qualities of slides. TCT are suitable for early diag2 nosis of cervical carcinoma and high grade squamous intraep ithelial lesion and is highly sensitive for cervical carcino2 ma screening. Key words TCT; quality control; cervical carcinoma Modern Oncology 2009, 17 (08) : :( TCT) : 18500,,, HPV DNA : TCT98. 8% (18287 /18500), TCT 100% (18 /18), C IN397% (30 /31), C IN290% (42 /46), HPVDNA : TCT, TCT, TCT; ; R A (2009) , 23 [ 1 ],,,, [ 2 ],, ( : ), ( ),,,,, 18500TCT,18-48,,, , (- ),,,,,,,( ) 1. 3 ( TCT), Thin2 p rep2000,,,,,,95% +, 10